Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 2

Ürocortin-2 ile sistolik, diyastolik fonksiyonlar ve koroner arter hastalığının ilişkisi: Gözlemsel bir çalışma

Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: An observational study

Pages
115–120
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But, DD (impaired relaxation pattern), or CAD (without myocardial infarction) seems to have no effect on Ucn-2 hormone levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The urocortin (Ucn) hormones have many important roles in the cardiovascular system.
📊
Key Findings & Data:Apart from systolic dysfunction (SD), there is no sufficient data on the relationship between serum Ucn-2 and diastolic dysfunction (DD), or coronary artery disease (CAD).
💡
Conclusion & Impact:But, DD (impaired relaxation pattern), or CAD (without myocardial infarction) seems to have no effect on Ucn-2 hormone levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The urocortin (Ucn) hormones have many important roles in the cardiovascular system. Apart from systolic dysfunction (SD), there is no sufficient data on the relationship between serum Ucn-2 and diastolic dysfunction (DD), or coronary artery disease (CAD). We investi- gated serum Ucn-2 levels in SD, DD, and CAD. Methods: In this observational cross-sectional study, study population was enrolled among outpatients who underwent coronary angiography with the pre-diagnosis of CAD. By examining the echocardiography 86 subjects were selected to study after coronary angiography. The subjects distributed over three groups to investigate the relationship between serum Ucn-2 and SD according to their ejection fraction (EF): subjects with moderate to severe SD (Group A, EF=33.6%), subjects with mild to moderate SD (Group B, EF=46.1%), and those without SD (Group C, EF=64.5%). Apart from these groups, the serum Ucn-2 levels were compared between subjects with and without DD (EF≥45%), and also com- pared between subjects with and without CAD (EF≥55%). Statistical analyses were performed using one-way ANOVA, Kruskal-Wallis, Chi- square, Mann-Whitney U, Spearman correlation and multiple regression analyses tests. Results: Serum Ucn-2 levels were decreased in Group A and were increased in Group B compared to Group C (9.4±3.4, 12.8±3.6 vs. 10.4±3.9 pg/ mL, respectively, p=0.003). Unlike SD; there was no significant difference in serum Ucn-2 levels between subjects with and without DD (11.4±4.1 vs 11.7±3.9 pg/mL, p=0.8) or CAD (10.7±4.7 vs 10.2±3.2 pg/mL, p=0.7). Conclusion: Ucn-2 is elevated in mild to moderate SD. But, DD (impaired relaxation pattern), or CAD (without myocardial infarction) seems to have no effect on Ucn-2 hormone levels.

Özet

Amaç: Urocortin (Ucn) hormonları kardiyovasküler sistemde önemli rol oynamaktadır. Sistolik işlev bozukluğu (SD) dışında, diyastolik işlev bozukluğu (DD) veya koroner arter hastalığının (KAH) serum Ucn-2 ile ilişkisine dair yeterli veri bulunmamaktadır. Bu çalışmamızda SD, DD ve KAH’da serum Ucn-2 düzeyini araştırdık. Yöntemler: Bir gözlemsel enine-kesitli olan bu çalışmanın popülasyonu KAH ön tanısı ile koroner anjiyografi işlemine alınan bireyler arasından belirlendi. Koroner anjiyografi sonrası ekokardiyografi yapılarak 86 kişi seçildi. Ucn-2 ile SD arasındaki ilişkiyi araştırmak için ejeksiyon fraksiyonu (EF) farklı üç grup oluşturuldu: orta-ileri düzey SD olanlar (Grup A, EF=%33.6), hafif-orta SD olanlar (Grup B, EF=%46.1) ve SD olmayanlar (Grup C, EF= %64.5). Ayrıca, DD sahip olan ve olmayanlar (EF≥ %45) arasında ve KAH’ı olan ve olmayanlar (EF≥ %55) arasında da Ucn-2 düzeyi karşılaştırıl- dı. İstatistiksel analizde tek yönlü ANOVA, Kruskal-Wallis, Ki-kare, Mann-Whitney U, Spearman korelasyon ve çoklu regresyon testleri kullanıldı. Bulgular: Grup C’ye göre, Ucn-2 düzeyinin Grup A’da azaldığı ve Grup B’de arttığı saptandı (Grup A, B ve C’de sırasıyla Ucn-2; 9.4±3.4, 12.8±3.6 ve 10.4±3.9 pg/mL, p=0.003). SD’den farklı olarak; Ucn-2 düzeyi bakımından, DD olan ve olmayanlar arasında (11.4±4.1 ve 11.7±3.9 pg/mL, p=0.8) veya KAH olan ve olmayanlar arasında (10.7±4.7 ve 10.2±3.2 pg/mL, p=0.7) anlamlı bir fark saptanmadı. Sonuç: Serum Ucn-2 düzeyi hafif-orta sistolik disfonksiyonda yükselmektedir. Ancak, DD (azalmış gevşeme bozukluğu) veya KAH’ın (miyokart enfarktüsü olmadan) serum Ucn-2 düzeyini etkilemediği görülmektedir.

🔖

Cite This Article

ERMİŞ, N., CANSEL, M., ATAŞ, H., AÇIKGÖZ, N., OTLU, B., TOPAL, E., YAĞMUR, J. (2022). Ürocortin-2 ile sistolik, diyastolik fonksiyonlar ve koroner arter hastalığının ilişkisi: Gözlemsel bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 2, 115–120. https://ajindex.com/articles/436476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995: 378; 287-92. [CrossRef] 2. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001; 27: 2843-8. [CrossRef] 3. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001; 19: 7570-5. [CrossRef] 4. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23: 71-7. [CrossRef] 5. Iino K, Sasano H, Oki Y, Andoh N, Shin RW, Kitamoto T, et al. Urocortin expression in the human central nervous system. Clin Endocrinol 1999; 50: 107-14. [CrossRef] 6. Baigent SM, Lowry PJ. mRNA expression profiles for corticotrophin- releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 2000; 25: 43-52. [CrossRef] 7. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002; 87: 340-6. [CrossRef] 8. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997; 272: H2115-22. 9. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001; 169: 177-83. [CrossRef] 10. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000; 275: 8508-14. [CrossRef] 11. Barry SP Lawrence KM, McCormick J, Soond SM, Hubank M, Eaton S, et al. New targets of urocortin-mediated cardioprotection. J Mol Endocrinol 2010; 45: 69-85. [CrossRef] 12. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal and renal effects in experimental heart failure. Eur Heart J 2005; 26: 2055-62. [CrossR